Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.
复制标题
肌层浸润性膀胱癌的新辅助免疫治疗、化疗和联合治疗：一项多中心真实世界回顾性研究
DOI：
10.1016/j.xcrm.2022.100785
复制
发表时间：
2022-11-15
影响因子：
14.3
通讯作者：
Zu, Xiongbing
中科院分区：
文献类型：
--
作者：
Hu, Jiao;Chen, Jinbo;Ou, Zhenyu;Chen, Haige;Liu, Zheng;Chen, Minfeng;Zhang, Ruiyun;Yu, Anze;Cao, Rui;Zhang, Enchong;Guo, Xi;Peng, Bo;Deng, Dingshan;Cheng, Chunliang;Liu, Jinhui;Li, Huihuang;Zou, Yihua;Deng, Ruoping;Qin, Gang;Li, Wenze;Wang, Lue;Chen, Tao;Pei, Xiaming;Gong, Guanghui;Tang, Jiansheng;Othmane, Belaydi;Cai, Zhiyong;Zhang, Chunyu;Liu, Zhi;Zu, Xiongbing
比较新辅助免疫治疗的疗效（tislelizumab），新辅助化疗（吉西他滨和顺铂）和新辅助联合治疗为了评估（tislelizumab + GC）在肌层浸润性膀胱癌（MIBC）患者中的疗效并探索疗效预测因素，我们进行了一项多中心、真实世界队列研究，该研究招募了253例接受新辅助治疗的患者（联合治疗98例，化疗107例，免疫治疗48例）。我们证明，与新辅助免疫治疗或化疗相比，新辅助联合治疗达到了最高的完全缓解率和病理学分期下调率。我们开发并验证了一个由治疗前临床特征组成的疗效预测模型，该模型可以确定接受新辅助联合治疗的候选人。我们还初步揭示，新辅助治疗后达到病理完全缓解的患者加上最大经尿道膀胱肿瘤切除术可能是安全的，接受膀胱保留治疗。总的来说，这项研究强调了基于tislelizumab的新辅助联合治疗对MIBC的益处。新辅助化学免疫疗法对膀胱癌患者是安全可行的。开发了新辅助化学免疫疗法的疗效预测模型。从大量和单细胞RNA测序中探索疗效生物标志物。新辅助免疫疗法与新辅助免疫疗法或化学疗法相比达到了最高的反应率。新辅助治疗加经尿道膀胱肿瘤最大电切术后病理完全缓解的患者可以安全地接受膀胱保留治疗。
To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi-center, real-world cohort study that enrolls 253 patients treated with neoadjuvant treatments (combination therapy: 98, chemotherapy: 107, and immunotherapy: 48) from 15 tertiary hospitals. We demonstrate that neoadjuvant combination therapy achieves the highest complete response rate and pathological downstaging rate compared with neoadjuvant immunotherapy or chemotherapy. We develop and validate an efficacy prediction model consisting of pretreatment clinical characteristics, which can pinpoint candidates to receive neoadjuvant combination therapy. We also preliminarily reveal that patients who achieve pathological complete response after neoadjuvant treatments plus maximal transurethral resection of the bladder tumor may be safe to receive bladder preservation therapy. Overall, this study highlights the benefit of neoadjuvant combination therapy based on tislelizumab for MIBC. Neoadjuvant chemoimmunotherapy is safe and feasible for patients with bladder cancer An efficacy prediction model for neoadjuvant chemoimmunotherapy is developed Efficacy biomarkers are explored from bulk and single-cell RNA sequencing In a multi-center, real-world study, Hu et al. demonstrate that neoadjuvant chemoimmunotherapy achieves the highest response rate, compared with neoadjuvant immunotherapy or chemotherapy. Patients who achieve pathological complete response after neoadjuvant treatments plus maximal transurethral resection of the bladder tumor may be safe to receive bladder preservation therapy.
登录
查看更多内容
对膀胱癌的新辅助化疗的共表达外推（Coxen）的随机II期研究（SWOG S1314； NCT02177695）。
DOI：
10.1158/1078-0432.ccr-20-2409
发表时间：
2021-05-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Flaig TW;Tangen CM;Daneshmand S;Alva A;Lerner SP;Lucia MS;McConkey DJ;Theodorescu D;Goldkorn A;Milowsky MI;Bangs R;MacVicar GR;Bastos BR;Fowles JS;Gustafson DL;Plets M;Thompson IM Jr
通讯作者：
Thompson IM Jr
5mC调节剂介导的分子亚型描绘了肿瘤微环境的特征并指导膀胱癌的精准医疗
影响因子：
9.3
作者：
Hu J;Othmane B;Yu A;Li H;Cai Z;Chen X;Ren W;Chen J;Zu X
通讯作者：
Zu X
影响因子：
6.2
作者：
Elting, LS;Cooksley, C;Bodurka, DC
通讯作者：
Bodurka, DC
影响因子：
28.4
作者：
Mezquita, Laura;Auclin, Edouard;Besse, Benjamin
通讯作者：
Besse, Benjamin
影响因子：
64.8
作者：
Mariathasan S;Turley SJ;Nickles D;Castiglioni A;Yuen K;Wang Y;Kadel EE III;Koeppen H;Astarita JL;Cubas R;Jhunjhunwala S;Banchereau R;Yang Y;Guan Y;Chalouni C;Ziai J;Şenbabaoğlu Y;Santoro S;Sheinson D;Hung J;Giltnane JM;Pierce AA;Mesh K;Lianoglou S;Riegler J;Carano RAD;Eriksson P;Höglund M;Somarriba L;Halligan DL;van der Heijden MS;Loriot Y;Rosenberg JE;Fong L;Mellman I;Chen DS;Green M;Derleth C;Fine GD;Hegde PS;Bourgon R;Powles T
通讯作者：
Powles T